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1tatins to Reduce Risk of Depression
e read with great interest the findings by Young-Xu and
o-workers on long-term use of statins to reduce the risk of
epression (1). Patients treated with statins had a lower incidence
f abnormal psychological scores. A 30% to 40% risk reduction for
epression was found in this group. At first glance, the effect of
tatins appears to relate to cholesterol reduction. However, in
ddition to inhibition of HMG-CoA reductase, certain statins
ere found to suppress the Th1-type cytokines interferon-gamma
IFN-) and interleukins (IL)-2 and -12, while promoting secre-
ion of Th-2 cytokines IL-4, IL-5, and IL-10 (2). Such data
avorably compare to results we have generated in vitro on
torvastatin to suppress IFN--mediated biochemical events in
eripheral blood mononuclear cells and in monocytes (3). Atorva-
tatin was shown to diminish in a dose-dependent manner activity
f indoleamine (2,3)-dioxygenase (IDO). Enzyme IDO is induc-
ble by IFN- and degrades the essential amino acid tryptophan via
he kynurenine pathway. Therefore, accelerated tryptophan deg-
adation by IDO activation is commonly observed in a broad range
f diseases associated with endogenous formation of Th1-type
ytokine IFN- (4), including patients with coronary heart disease
CHD) (5).
Because tryptophan is precursor of neurotransmitter
-hydroxytryptamine (serotonin), lowered tryptophan availability
ncreases the susceptibility of depression in patients (4); for
xample, in patients with colorectal cancer an association was
eported between lowered serum tryptophan related to immune
ctivation and impaired quality of life (6). Thus, when statins are
ble to block IDO and thereby increase tryptophan concentrations,
t is reasonable that statins would reduce the risk of depression in
HD patients with an accelerated tryptophan degradation (5).
hether statins improve tryptophan metabolism in patients is
orth being tested in clinical trials.
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e are pleased that Dr. Wirleitner and colleagues found our
eport (1) of interest. We would like to point out that in our study
he effects of statins on psychological well-being appeared to be
ndependent of both cholesterol reduction and baseline cholesterol
evel. Because the effects of statins on the psychological well-being
f our patients were related to the lipophilicity of the statin and not
o the level of cholesterol reduction, we postulate that the biolog-
cal effect may be mediated by statin’s direct effect on the central
ervous system. By inhibiting HMG-CoA reductase in neuronal
ells, statins could potentially alter cellular cholesterol content and
ipid membrane rafts. This could lead to changes in neuronal
unction as manifested in psychological well-being. Another con-
equence of HMG-CoA reductase inhibition is inhibition of
ignaling molecules that depend upon isoprenylation for proper
unction. In this respect, statins could alter the balance of Th1/
h2 cell population, leading to potential blockade of indoleamine
ioxygenase. Indeed, statins have been shown to decrease Th1-
ediated inflammatory response in an autoimmune mouse model
f multiple sclerosis (2). This effect was observed without signif-
cant changes in serum cholesterol levels. Thus, it is possible that
he “antidepressant” effect of statins in our patient population
ould be mediated by a cholesterol-independent immunomodula-
ory effect of statins.
We are encouraged by Dr. Wirleitner and colleagues’ letter,
hich supports our clinical observation by providing another clue
o a potential biological mechanism. We do agree with them that
t should be tested in clinical trials whether statins improve
ryptophan metabolism, as that would provide data to support or
efute the proposed biological mechanism.
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